Elicio Therapeutics Inc. (ELTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has a cash flow conversion efficiency ratio of -4.155x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.80 Million) by net assets ($1.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Elicio Therapeutics Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Elicio Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elicio Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicio Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Formosa Electronic Industries
TWO:8171
|
-0.016x |
|
Bathurst Resources Ltd
F:B0R
|
0.017x |
|
Credit Clear Ltd
AU:CCR
|
0.052x |
|
SANUWAVE Health, Inc. Common Stock
NASDAQ:SNWV
|
0.216x |
|
DASAN Networks Inc
KQ:039560
|
0.044x |
|
Libertas 7 SA
MC:LIB
|
-0.008x |
|
Rein Therapeutics Inc
NASDAQ:RNTX
|
-0.295x |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Elicio Therapeutics Inc. from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Elicio Therapeutics Inc. (ELTX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.64 Million | $-36.95 Million | -22.587x | -789.28% |
| 2024-12-31 | $-11.31 Million | $-37.07 Million | 3.277x | +213.99% |
| 2023-12-31 | $11.37 Million | $-32.69 Million | -2.875x | -15.55% |
| 2022-12-31 | $8.91 Million | $-22.18 Million | -2.488x | -747.05% |
| 2021-12-31 | $81.51 Million | $-23.94 Million | -0.294x | -216.07% |
| 2020-12-31 | $-90.45 Million | $-22.89 Million | 0.253x | -80.87% |
| 2019-12-31 | $-18.59 Million | $-24.59 Million | 1.323x | +411.96% |
| 2018-12-31 | $18.91 Million | $-8.02 Million | -0.424x | -199.94% |
| 2013-12-31 | $4.46 Million | $1.89 Million | 0.424x | +68.83% |
| 2012-12-31 | $4.24 Million | $1.07 Million | 0.251x | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more